Plaquex Therapy

micelles-35724__480.png

What is Phosphatidylcholine?

Plaquex is a compounded medicine that contains polyunsaturated phosphatidylcholine (PC). PCs makes up all the cell membranes in the body (see photo below). Between these PCs are signaling molecules which allow for transportation of hormones, neurotransmitters and lipids into the cell. PCs are responsible for keep our cell membranes fluid. 

PCs also make up smaller transport vehicles for cholesterol, such as HDL and LDL. Theses low density (LDL) or high density lipoproteins (HDL) are crucial for our wellbeing. These molecules allow the body to remain in homeostasis, for our hormones to remain balanced, and the  immune system to function properly. 

As we age, the PC in the cell membranes become less fluid and stiffer due to exposure to  toxins, free radical oxidation, heavy metals, blood pressure increases, spikes in blood sugar and cortisol (the stress hormone). The damage reduces the surface tension of the vehicles that carry cholesterol which allows for more circulating LDL (bad) and less HDL (good). HDL cholesterol is responsible for protecting our arteries from damage and creation of our sex hormones. LDL is responsible for artery plaque deposits, which are responsible for heart attacks and some strokes. 

The liver is responsible for creation of PC molecules. The molecuels are very high energy molecules and as we age our bodies make less of the substance. Liver damage due to poor diet, substance abuse or chronic stress decrease our bodies supply of PC. 

What does Phosphatidylcholine do For Our Bodies?

Plaquex therapy delivers PCs intravenously to restore cell membrane fluidity and function. It has been studied since the 1950s for the treatment of atherosclerosis (hardening of arteries), angina pectoris (chest pain), coronary arteries plaque formation (plaques that cause heart attacks) and leg claudication (leg pain due to low blood flow).

Besides studies on the vascular system, PCs are helpful for all cell types. Liver, kidney and skin cells benefit from the cell membrane restoring effects of PCs. 

Some noted benefits of IV plaque:

  • Reverses/prevents the risk of plaque production

  • Helps to restore immunocompetence

  • Enhances sexual competence

  • Retards progression of aging

  • Improves impaired renal and liver function

  • Reduces high blood pressure

  • Reduces cholesterol and “cleans” arteries

What to expect from treatment?

A physical exam and lab evaluation is needed to determine that treatment is warranted and safe. Lab interpterion and treatment determination is necessary for treatment. 

Standard Plaquex therapies range from 20-40 infusions spaced 3-4 days apart. In more serve cases of cardiovascular disease more treatments (45+) may be necessary. 

Maintenance of therapy depends on condition treated and goals of treatment. Typical maintenance can include 10-20 infusions per year. If symptoms arise another course of treatment may be indicated. 

Possible side effects include bruising or bleeding at injection site, inflammation of the vein/phlebitis, and diarrhea. Slow infusions and workup minimize the chances of side effects. 

 

References: (www.plaquex.net)

1.     Ehrly, A.M. Report no. 842276 of March 17, 1975 – and R. Blendin in: Phosphatidylcholine, H. Peeters (ed.) Springer: Berlin  1976, 228-236
 Blagosklonov, A.S. et al. Kardiologiya 26 (1986) 35-38
3 Nei’mark Al, Zhukov, VN et al.  Use of isradipine and EPL for protection of the kidney during extracorporal lithotripsy
Urologiia I Nefrologiia. (6):19-21, 1998 Nov-Dec
4 Kuntz, E. 

2.     Salvioli, G. et al. Il Fegato 21 (1975) 5-25 and: 4th Int. Sympos. Atheroscl., Tokyo 1976 

3.     Diab. Obes. Hyperlipoprot., Cupaldi, V. et al. (eds.), Academic Press: New York 1987 

4.     Salvioli, G.  Scand J. Gastroenterology 12 (1977) 841-847
 Salvioli, G. et al. Gut 19 (1978) 844-850
 Gaskina, T.K. et al. Voprosy meditsinskoi khimii 331 (1987) 96-99

5.     Klemm, J. In: Phosphatidylcholine. H. Peeters (ed.) Springer: Berlin 1976, 237-243
 

6.     Luczac, Z., R. Leutschaft.  Unpublished report no. 842762
 

7.     Pristautz, H.  Munch. Med. Wschr. 117 (1975) 583-586
 Hevelke, G. et al. 

8.     Serkova, V.K. Klin. Med. (Moscow) 64 (1986) 91-95
 Spesivtseva, V. G. et al., Lipostabil Symposium Moscow, Nov. 1984
 Kalmykova, V.I., E. B. Zakharova, Sov. Med. 4 (1989) 5-9

9.     Gendai no Shinryo 22 (1980) 189-192 and 1461-1465
 Fasoli, A.  Therap. Select. Risk/Benefit Assess. Hypolipid. Drugs
 G. Ricci et al. (eds.) Raven Press: New York 1982, 257-262

Disclaimer: All information on OneBodyMedicine.com is for educational purposes. Information about certain medical conditions have not been evaluated or approved by the FDA. One Body Medicine cannot and does not contain medical advice. The medical information is provided for general informational and educational purposes only and is not a substitute for professional advice. Accordingly, before taking any actions based upon such information, we encourage you to consult with the appropriate medical professionals. We do not provide any kind of medical advice. The use or reliance of any information contained on this site is solely at your own risk.